Cardio Diagnostics Holdings Inc. · NASDAQ:CDIO
Cardio Diagnostics — Mana Capital Acquisition — SPAC Merger (August 2022)
29 slides from Cardio Diagnostics's SPAC merger presentation, Aug 26, 2022
Slide 1: Mana Capital Acquisition Corp. / Cardio Diagnostics Investor Presentation
MANA CAPITAL Acquisition Corp. @ CardioDiagnostics Transforming Cardiovascular Health Through Our Al-Driven Integrated Genetic-Epigenetic Engin INVESTOR PRESENTATION August 2022
Slide 2: Disclaimer
Disclaimer General This purposes and only to ass the proposed business Business i Capital \Corp.{*Mana Capital” and Cardlo Diagnostics, Inc {together wit ts subsidiary, "Cardio" and related transactions, which willbe submitted to ‘ose deol Van Capo etcraleation od not or ae pues Noting cored hs rams
Slide 3: Disclaimer Continued
Disclaimer Continued Non-GAAP Financial Information This Includes certain fnanctal on not presented in th generally accepted principles (GAAP), including, but not limited to, fre cash low and other matric. The non-GAAP financial information included herein does nt present financial performance in ac
Slide 4: Risk Factors
Risk Factors Inevaluating the Business Combination tobe considered and voted on atthe specal meeting, you shoul consider theriskfactors set the sect "Risk Factors Included te Form -4/praxy statement fled by Mana Capital. The occurrence of one ar more of the event or eltcumstances esrb ina secon ane
Slide 5: Risk Factors Continued
Risk Factors Continued Risks Related to the Business Combination and being a Public Company + Going pubic through ammerger rater than: offering presents risks investors tour the business we maybe requted to take write-downs or write-off, wgandi or other charges that could neg ur financial coalition,
Slide 6: Introduction to Cardio Diagnostics
Introduction to Cardio Diagnostics THE COMPANY e Making cardiovascular disease prevention and early detection more accessible, personalized, and precise e Developed an Al-driven Integrated Genetic-Epigenetic Engine™ that enables the identification of robust genetic-epigenetic biomarkers and their tr
Slide 7: Business Combination Overview (2)
Business Combination Overview (2) TRANSACTION SUMMARY + OnMay 27, 2022, Cardio entered into a definitive agreement to merge with Mana Capital, valuing Cardio at apro forma enterprise value of $104.1 million, the “Business Combination’. ‘+ Inaddition to $45 million held in the Mana Capital trust acco
Slide 8: Cardiovascular Disease and Associated Co-Morbidities
Cardiovascular Disease and Associated Co-Morbidities Cardiovascular disease (CVD) is the leading cause of death in the US, and is responsible for nearly $1 billion/day in medical costs + lost productivity CORONARY HEART DISEASE (CHD) The most common type of CVD 20+ million adults have CHD, the major
Slide 9: Two Types of DNA Biomarkers Power Our Approach
Two Types of DNA Biomarkers Power Our Approach GENETICS (SINGLE NUCLEOTIDE POLYMORPHISMS) e Inherited from parents e < 20% of risk for cardiovascular disease is driven by genetics e Does not change over time (i.e., not dynamic) EPIGENETICS (DNA METHYLATION) e Influenced by lifestyle & environment AL
Slide 10: Clinicians' Current Approach to Cardiovascular Disease
Clinicians’ Current Approach to Cardiovascular Disease Currently, risk for CVD is assessed using two common lipid-based clinical tests LIPID-BASED TESTS ARE NOT EFFECTIVE FOR SEVERAL REASONS: FRAMINGHAM RISK SCORE (FRS) The average sensitivity of FRS & PCE was found to ° Age © Total cholesterol be 4
Slide 11: Our AI-Driven Integrated Genetic-Epigenetic Engine
Our Al-Driven Integrated Genetic-Epigenetic Engine™ Designed and built over the past decade M2 BIG DATA HIGH-PERFORMANCE DOMAIN EXPERTISE PRODUCT COMPUTING, ML/Al AND DOMAIN EXPERTISE Billions of genetic, epigenetic Non-linear Lab translation of assays Lab profiling & clinical data points + data min
Slide 12: Epi+Gen CHD: The Only Epigenetics-Based Test For Coronary Heart Disease
Epit+Gen CHD™: The Only Epigenetics-Based Test For Coronary Heart Disease e Epi+Gen CHD™ is Cardio Diagnostics’ first product that was developed using our Al-driven Integrated Genetic-Epigenetic Engine™. e Epi+Gen CHD™ assesses 3-year risk for coronary heart disease (CHD), the most common type of he
Slide 13: Recognition of Epi+Gen CHD and the Company
Recognition of EpitGen CHD™ and the Company Winner Biotech Innovation Showcase Award 2019 ERK nature research awards IOWA BIOTECH RAGRTUK SHOWCASE & CONFERENCE Saueie tener, @® CardioDiagnostics
Slide 14: Epi+Gen CHD: Clear, Key Differentiations for Risk Assessment
EpitGen CHD™: Clear, Key Differentiations for Risk Assessment SENSITIVE, EPIGENETICS BASED TEST CORONARY HEART DISEASE SPECIFIC PHYSICIAN ORDERED AND/OR INTERPRETED AT-HOME TESTING AVAILABLE MULTIPLE DNA BIOMARKERS-BASED TEST @® CardioDiagnostics Vv Vv Vv Vv Vv 2X << 8 (NASDAQ: ME) *% *% *X << x x x
Slide 15: Epi+Gen CHD: A $51B US Total Addressable Market
Epi+Gen CHD™: A $51B US Total Addressable Market" © 2 We expect to accelerate the Epi+Gen CHD™ is recommended We intend to accelerate the adoption adoption of EpitGen CHD™ for adults ages 35-75 who have not of EpitGen CHD™ by: across several channels including been diagnosed with coronary e Developi
Slide 16: Epi+Gen CHD: Strategically Driving Adoption Through Four Key Channels
EpitGen CHD™: Strategically Driving Adoption Through Four Key Channels INNOVATIVE TELEMEDICINE CONCIERGE PRACTICES, HEALTH SYSTEMS EMPLOYERS KEY DRIVERS. e Pandemic-driven growth e Convergence of e Striving to diversify e Increasingly view in virtual care forward-leaning providers, business models a
Slide 17: A Scalable Testing & Reporting Process to Fulfill Increasing Demand
EpitGen CHD™: A Scalable Testing & Reporting Process to Fulfill Increasing Demand REMOTE Po] Telemedicine provider At-home lancet sample orders test for patient collection kit shipped to patient : : e eo > 2) Collect blood : , sample r ° ° Ship blood sample overnight to lab Provider/healthcare Lance
Slide 18: Supply Chain & Laboratory Strategy
Supply Chain & Laboratory Strategy SAMPLE COLLECTION KIT CONTENTS & ASSEMBLY: e Common kit contents that can be sourced from multiple distributors e Identified multiple distributors to diversify supply chain e Most kit contents are shelf-stable for years and can be sourced well in advance e Agreemen
Slide 19: Gross Margin Expansion Opportunity
Gross Margin Expansion Opportunity Potential lab Process larger acquisition sample batches Internally integrate sample collection kit assembly and fulfillment @® CardioDiagnostics Bulk shipping of sample collection kits and/or samples Increase processing automation
Slide 20: The Integrated Genetic-Epigenetic Engine can be Leveraged Repeatedly
The Integrated Genetic-Epigenetic Engine™ can be Leveraged Repeatedly Assumes $350/test | Assumes one patient could be tested with multiple tests“ *Represents expected launch date LAUNCHED EPI+GEN CHD CHD DETECTION 146M adults $51B @® CardioDiagnostics 2022* 2nd Half 157M adults $55B 2023* 2023* 202
Slide 21: FDA Regulatory Pathway Enables Other Labs to Process Epi+Gen CHD
FDA Regulatory Pathway Enables Other Labs to Process EpitGen CHD™ () ONGOING ONGOING 70-80 DAYS 5 DAYS Determine appropriate FDA pathway based on ‘Assemble FDA pre-submission to receive ‘Submit pre-submission to FDA for detailed Receive FDA comments & meet with FDA input from FDA advisor & counsel f
Slide 22: Pursuing A New Standard of Care for Cardiovascular Health
EpitGen CHD™: Pursuing A New Standard of Care for Cardiovascular Health EVIDENCE BUILDING KOLs' & (e.g. research studies, REIMBURSEMENT health economics) CONSULTANT CODE, GAG ENGAGE COVERAGE PAYORS & PAYMENT © =n cy ONGOING ONGOING 6-12 MONTHS 2.5-3 YEARS @® CardioDiagnostics (2) KOLs:Key Opinion Le
Slide 23: Robust Short-Term & Long-Term Strategic Initiatives
Robust Short-Term & Long-Term Strategic Initiatives GROWTH STRATEGIES REDUCE VARIABLE COSTS MANAGE RISKS INCREASE REVENUE LAB ACQUISITION PURSUE FDA PATHWAY PAYOR COVERAGE TARGET MULTIPLE REVENUE CHANNELS LAUNCH MULTIPLE SYNERGISTIC PRODUCTS, @® CardioDiagnostics Vv Vv {€ << 8 8 {< << 6 23
Slide 24: Strong Leadership
Strong Leadership Experienced leadership, complementary backgrounds & vision to succeed Warren Hosseinion, MD Chairman President, Nutex Health, Inc. (NUTX)- $2.20B market cap", Co-founder of Apollo Medical Holdings (AMEH) -$2.58B market cap, Director and former CEO of Clinigence Holdings (CLNH), MD
Slide 25: Team Continued
Team Continued Rob Philibert, MD PhD Co-founder, CMO & Director 15+ years in epigenetics and clinical translation, Co-inventor of the Integrated Genetic-Epigenetic Engine™, MD & PhD in Neuroscience from the University of lowa @® CardioDiagnostics Elisa Luqman, JD MBA CFO Chief Legal Officer (SEC), N
Slide 26: Team Continued
Team Continued Tim Dogan, PhD cTO 11+ years in high performance computing systems, Co-inventor of the Integrated Genetic-Epigenetic Engine™, PhD in Mechanical Engineering from the University of lowa @® CardioDiagnostics Khullani Abdullahi, JD VP of Revenue & Strategy 12+ years in commercializing com
Slide 27: Comparable Companies
Comparable Companies 2023 REVENUES (CONSENSUS ESTIMATE) US($mm) MARKET CAP VS 2023 REVENUE (CONSENSUS EST.) L209] Louy) . NVTA (Invitae Corp) te) INVITAE Lo © MYGN (Myriad Genetics) VCYT (Veracyte Inc.) Wveracyte. EXACT. EXAS (Exact Sciences) SCIENCES Mbt Cap. 36,3561 NTRA (Natera Inc.) Snatera GH (
Slide 28: Financial Projections
Financial Projections FINANCIAL PROJECTIONS Q2-Q4 2022 2023 2024 2025 2026 TOTAL REVENUE $784,250 $5,151,000 $11,902,000 $63,870,000 $105,222,000 GROSS PROFIT $313,700 $2,060,400 $4,760,800 $25,548,000 $42,088,800 OPERATING PROFIT ($2,148,745) ($4,989,600) ($6,489,200) $5,698,000 $14,738,800 NET INC
Slide 29: Financial Projections
Financial Projections © Included in this presentation are Cardio’s estimates ofits financial performance for the fiscal years 2022 through 2026 (the “Financial Projections"), Based on information known as of the date of this presentation. The Financial Projections were prepared by Cardio's managemen